Scarica l'app Stockscreener
11.83
10.78%
-1.43
Dopo l'orario di chiusura:
11.83
Precedente Chiudi:
$13.26
Aprire:
$12.52
Volume 24 ore:
662.79K
Relative Volume:
1.50
Capitalizzazione di mercato:
$645.01M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-11.72%
1M Prestazione:
-6.85%
6M Prestazione:
-50.29%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$11.64
$12.80
Intervallo di 1 settimana:
$11.64
$14.39
Portata 52W:
$11.10
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-785-8308
Indirizzo
245 MAIN STREET, CAMBRIDGE
Confronta BCAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
11.83 | 645.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com
Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks
Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World
Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks
Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India
Bank of New York Mellon Corp Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc QTRLY Loss Per Share $0.39 - MarketScreener
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - Enid News & Eagle
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - GlobeNewswire
Skandinaviska Enskilda Banken AB publ Purchases Shares of 38,035 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register
Cantor Fitzgerald Reiterates “Overweight” Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus Price Target from Analysts - Defense World
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics - Investing.com India
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth - Yahoo Finance
19,008 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Rhumbline Advisers - Defense World
Bicara Therapeutics Inc.’s (NASDAQ:BCAX) Lock-Up Period Set To Expire on March 12th - Defense World
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus PT from Analysts - Defense World
Bicara Therapeutic, Inc. announced that it has received $108.234983 million in funding from a group of investors - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Receives Outperform Rating from Wedbush - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 8.6%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 7.3%Should You Buy? - MarketBeat
Wedbush Reiterates Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Announces First Patients Enrolled in - GlobeNewswire
Major Cancer Treatment Breakthrough? Phase 2/3 Trial Launches for Advanced Head & Neck Cancer - StockTitan
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Investing.com UK
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to Strong-Buy at Wedbush - MarketBeat
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Wedbush - MarketBeat
Wedbush Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wedbush Upgrades Bicara Therapeutics (NASDAQ:BCAX) to “Strong-Buy” - Armenian Reporter
Bicara Therapeutics (BCAX) to Release Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - Nasdaq
Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 9.7%Should You Buy? - MarketBeat
Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN
Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):